Susan Steen
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $244,844 of the $341,260 with a category attached, or 71.7%. 60 manufacturers reported payments, led by Lilly USA, LLC at 32.6% of the total. Reporting peaked in 2024 at $108,119 and has fallen 57.7% since, to $45,760 in 2025. Among neurology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,962 payments — averaging $173.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$111K
- Eisai Inc.$70K
- Otsuka America Pharmaceutical, Inc.$67K
- AbbVie$40K
- Biogen$11K
- Biohaven Pharmaceuticals, Inc.$8K
- plus $34K from 54 others
Across 190 payments — averaging $37,785 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$5.1M
- Biogen$982K
- Genentech, Inc.$416K
- E.r. Squibb & Sons, L.L.C.$414K
- AbbVie$94K
- Novo Nordisk AS$91K
- plus $131K from 5 others
What the payments were for
- Consulting fees$36,02111%
- Speaking & faculty fees$244,84472%
- Grants$420%
- Travel & lodging$25,7828%
- Food & beverage$34,56510%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$341,260 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $134,407 |
| NeuproRotigotine | 16 | $13,267 |
| Memantine Hcl | 122 | $3,239 |
| Donepezil Hcl | 201 | $2,091 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 54 | $884 |
| Galantamine ErGalantamine Hbr | 12 | $862 |
| Quetiapine Fumarate | 39 | $809 |
| Levetiracetam | 18 | $721 |
| Escitalopram Oxalate | 77 | $677 |
| Duloxetine Hcl | 27 | $644 |
| Gabapentin | 25 | $441 |
| Divalproex Sodium | 17 | $409 |
| Mirtazapine | 12 | $260 |
| Galantamine Hbr | 13 | $244 |
| RizatriptanRizatriptan Benzoate | 15 | $219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Neupro | $5,954 | $13,26716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,434 neurology providers in Florida.
Other neurology in Tampa
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Mark CascioneTampa$1.2M
- Tuan VuTampa$1M
- Katherine StandleyTampa$735K
- Rossitza ChichkovaTampa$294K
- Brody HenkelTampa$262K
- Jennifer JainTampa$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.